- Home
- DTF vs ALXO Comparison
DTF vs ALXO Comparison
Compare DTF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- ALXO
- Stock Information
- Founded
- DTF 1991
- ALXO 2015
- Country
- DTF United States
- ALXO United States
- Employees
- DTF N/A
- ALXO N/A
- Industry
- DTF Investment Managers
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- ALXO Health Care
- Exchange
- DTF Nasdaq
- ALXO Nasdaq
- Market Cap
- DTF 79.8M
- ALXO 79.7M
- IPO Year
- DTF N/A
- ALXO 2020
- Fundamental
- Price
- DTF $11.30
- ALXO $1.42
- Analyst Decision
- DTF
- ALXO Strong Buy
- Analyst Count
- DTF 0
- ALXO 6
- Target Price
- DTF N/A
- ALXO $3.30
- AVG Volume (30 Days)
- DTF 21.1K
- ALXO 342.6K
- Earning Date
- DTF 01-01-0001
- ALXO 11-07-2025
- Dividend Yield
- DTF 3.64%
- ALXO N/A
- EPS Growth
- DTF N/A
- ALXO N/A
- EPS
- DTF 0.44
- ALXO N/A
- Revenue
- DTF N/A
- ALXO N/A
- Revenue This Year
- DTF N/A
- ALXO N/A
- Revenue Next Year
- DTF N/A
- ALXO N/A
- P/E Ratio
- DTF $24.34
- ALXO N/A
- Revenue Growth
- DTF N/A
- ALXO N/A
- 52 Week Low
- DTF $10.29
- ALXO $0.40
- 52 Week High
- DTF $11.19
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- DTF 45.72
- ALXO 47.36
- Support Level
- DTF $11.27
- ALXO $1.29
- Resistance Level
- DTF $11.35
- ALXO $1.56
- Average True Range (ATR)
- DTF 0.06
- ALXO 0.17
- MACD
- DTF -0.01
- ALXO 0.01
- Stochastic Oscillator
- DTF 19.05
- ALXO 57.38
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.